3 Houston innovators to know this week

WHO'S WHO

This week's roundup of Houston innovators includes Sarah "Sassie" Duggleby of Venus Aerospace, Youngro Lee of Brassica, and Le Dam of myAvos. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from rocket science to fintech — recently making headlines in Houston innovation.

Sarah "Sassie" Duggleby, CEO and co-founder of Venus Aerospace

Sarah "Sassie" Duggleby of Venus Aerospace joins the Houston Innovators Podcast this week. Photo courtesy of Venus

Sarah "Sassie" Duggleby and her husband were living in Japan and considering a trip back to Texas and wishing there was a faster option than a full day of international travel — with their kids, no less. That's when Andrew Duggleby told Sassie that there actually might be an engine that could do that.

Flash forward a few years, and the husband-wife team has built a company around that idea. Venus Aerospace, originally founded in California, relocated to Houston in 2021 to establish their company in an ecosystem with the tools to advance their tech — and give their employees a good work-life balance, Sassie Duggleby explains on the Houston Innovators Podcast.

"We knew we had to find a location where we could test our engine and still be home for dinner," she says on the show. "Our company vision is 'home for dinner.' We want to fly you across the globe and have you home for dinner. And, if you work for us, we want you home for dinner." Read more.

Youngro Lee has announced funding for his latest fintech endeavor. Photo courtesy

Youngro Lee is no stranger to shaking up the finance world with a new tech-based way of doing business. One of the founders of NextSeed, Lee's newest mission is providing "investment infrastructure as a service" with his company, Brassica, which just raised $8 million in seed funding.

“The future of finance will depend on the ability of trustworthy institutions to provide secure and seamless transitions between traditional financial services and web3 innovations while complying with strict regulations and still providing great customer experience,” says Lee in the news release.

Houston-based Mercury Fund led the round with several other investors participating. Read more.

Le Dam, CEO and founder of OptiChroniX

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

After years on the West Coast, Le Dam has returned to her adopted hometown of Houston — just in time to launch a new app dedicated to providing health resources and information to its users.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. Read more.

The myAvos app has been designed by behavioral health scientists to set users up for long, healthy lives. Photo via Canva

Houston innovator launches holistic health and cognitive care app

download now

Meet Laura. She’s not human, but she could be the key to your aging healthfully. She’s the digital wellness coach on myAvos, a groundbreaking app that launched this week from OptiChroniX.

Now meet Le Dam, the woman behind the app. Dam is a medical doctor, as well as CEO and co-founder of OptiChroniX. While practicing medicine in her birthplace of Australia, Dam realized that her life of prescribing medications to patients who were already sick was not how she had envisioned helping people. She knew that prevention, using the five pillars of healthy aging — nutrition, activity, sleep, health, and stress — was the way to keep patients fit and happy into their golden years.

She returned to California, where she lived after leaving Houston as a youth, to work at a startup with the goal of one day heading a company of her own. She met Swiss-based COO and co-founder, Rene Gilvert, on LinkedIn.

“He was looking for a medical doctor to join his startup,” Dam recalls. “We were so well aligned that we decided to join forces.” Now, the team works remotely in locations ranging from Dam’s home in Houston to Portugal.

When the pandemic happened, Dam took the opportunity to leave the Silicon Valley and work remotely from Houston, a return that she says was always her end goal.

“I always knew that I wanted to build my business in Houston,” Dam says, mentioning the assets of the world’s largest medical center, a thriving startup community, and diverse population for whom she wants to build her technology.

myAvos pairs with a user’s smart watch and harnesses their health information such as physical activity and hours slept. The user can also input additional information such as blood test results and meals eaten. The app analyzes the information provided and assesses the user’s risk for chronic illness later in life. From there, Laura coaches them on what changes they can make to live healthier lifestyles. The app even reminds users when to take their medications and shares information with designated caregivers.

The myAvos app has a comprehensive approach to health. Screenshots via avos.health

The app has been designed by behavioral health scientists to understand why you’re not exercising enough or eating right and can offer personalized motivations to get users off the couch.

Right now, the focus is on potential dementia and cognitive impairment, says Dam, but in the future, myAvos will more holistically target all preventable chronic illnesses. But dementia is one of the major causes of disability among older people around the world and people living with it is expected to triple by 2050.

“If we can empower people with health literacy, we really believe we can prevent chronic disease,” says Dam. “Forty percent of dementia is preventable. A lot of these chronic diseases are preventable. Even diabetes can be reversible.”

And she points out that the changes that can be made to help cognitive health can affect other systems as well.

“We really want to empower the individuals,” Dam says. “If we can empower people with health literacy, we really believe we can prevent chronic disease.”

And myAvos is the key. The app is based on a subscription model, allowing users full access to a risk calculator, monthly cognitive assessments, personalized lifestyle guidance, and even fun brain games to keep them sharp. It may turn out that a visit with Laura a day will keep the doctor away long into your later years.

Le Dam moved from California to Houston to build her company. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings